The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes
Open accessAbstract
OBJECTIVE—Mealtime amylin replacement with the human amylin analog pramlintide, as an adjunct to mealtime insulin replacement, reduces postprandial glucose excursions in patients with type 2 diabetes. The aim of the present study was to assess the long-term efficacy and safety of pramlintide in this patient population. RESEARCH DESIGN AND METHODS—In a 52-week, double-blind, placebo-controlled, parallel-group, multicenter study, 656 patients with type 2 diabetes (age 57 ± 10 years, diabetes duration 12 ± 7 years, BMI 34.0 ± 7.0 kg/m2, HbA1c 9.1 ± 1.2%, mean ± SD) treated with insulin (alone or in combination with sulfonylureas and/or metformin) were randomized to receive additional preprandial subcutaneous injections of either placebo or pramlintide (60 μg TID, 90 μg BID, or 120 μg BID). RESULTS—Treatment with pramlintide 120 μg BID led to a sustained reduction from baseline in HbA1c (−0.68 and −0.62% at weeks 26 and 52, respectively), which was significantly greater than that seen with placebo (P < 0.05). The proportion of patients achieving an HbA1c <8% was approximately twofold greater with pramlintide (120 μg BID) than with placebo (46 vs. 28%, P < 0.05). The glycemic improvement with pramlintide 120 μg BID was accompanied by a mean weight loss (−1.4 kg vs. +0.7 kg with placebo at week 52, P < 0.05) and occurred without an overall increase in the severe hypoglycemia event rate. The most common adverse event associated with pramlintide use was transient, mild-to-moderate nausea. CONCLUSIONS—Mealtime amylin replacement with pramlintide 120 μg BID, as an adjunct to insulin therapy, improves long-term glycemic and weight control in patients with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials have shown a reduction in HbA 1c (0.3-0.4% [3-4 mmol/ mol]) and modest (1 kg) weight loss (251-254).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [253]
Experimental — accuracy not yet measuredIn the citing paper
“Somewhat greater weight loss was noted in type 2 diabetic patients treated with pramlintide.212”
From Obesity‐Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment: A Position Paper of The Obesity Society and the American Society of Hypertension (2013) · cites this paper as [212]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90605-w · Cited by 807
Epidemiology of severe hypoglycemia in the diabetes control and complications trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)80085-z · Cited by 807
Hollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Weiss, S. R., Crockett, S. E., Kaplan, R. A., Comstock, J., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1288 · Cited by 654
Self-citationEfficacy of Metformin in Type II Diabetes
Garber, A. J., Duncan, T. G., Goodman, A. M., Mills, D. J., & Rohlf, J. L. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00254-4 · Cited by 523
Association, A. D. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.775 · Cited by 464
Whitehouse, F., Kruger, D. F., Fineman, M., Shen, L., Ruggles, J. A., Maggs, D. G., Weyer, C., & Kolterman, O. G. (2002) · Diabetes Care · doi:10.2337/diacare.25.4.724 · Cited by 264
Self-citationStandards of Medical Care for Patients With Diabetes Mellitus
American Diabetes Association (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s33 · Cited by 264
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 308
Pramlintide Reduces the Risks Associated with Glucose Variability in Type 1 Diabetes
Kovatchev, B. P., Crean, J., & McCall, A. L. (2008) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2007.0295 · Cited by 10
Herrmann, K., Shan, K., Brunell, S. C., & Chen, S. (2014) · Endocrine Practice · doi:10.4158/ep13477.or · Cited by 9
In Silico Comparative Study of Human and Porcine Amylin
Alves, N. A., & Frigori, R. B. (2018) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.8b09363 · Cited by 9
Green, D. E. (2007) · Clinical cornerstone · doi:10.1016/s1098-3597(09)60008-9 · Cited by 9
Frigori, R. B. (2014) · Physical Review E · doi:10.1103/physreve.90.052716 · Cited by 9
Practical Use of Exenatide and Pramlintide for the Treatment of Type 2 Diabetes
Meade, L. T. (2009) · Journal of Pharmacy Practice · doi:10.1177/0897190009333164 · Cited by 9
“In consideration of the number of injections a day and cost to the patient, twice-daily dosing may be a more cost effective alternative, which would also minimize the number of injections a day.(25) Originally pramlinitide was only available in vial and syringe, which made dosing more difficult for patients and provid…”
BackgroundDoupis, J., & Panagoulias, G. S. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s34089 · Cited by 8
Pharmacotherapy for chronic obesity management: a look into the future
Abdel-Malek, M., Yang, L. Y., & Miras, A. D. (2023) · Internal and Emergency Medicine · doi:10.1007/s11739-023-03237-4 · Cited by 12
New drugs for the treatment of type 2 diabetes
Chowdhury, T. A., & Hossain, B. (2007) · British Journal of Hospital Medicine · doi:10.12968/hmed.2007.68.4.178 · Cited by 8
PHAST: Protein-like heteropolymer analysis by statistical thermodynamics
Frigori, R. B. (2017) · Computer Physics Communications · doi:10.1016/j.cpc.2017.01.021 · Cited by 8
Therapeutic Options that Provide Glycemic Control and Weight Loss for Patients with Type 2 Diabetes
Blevins, T. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.01.2111 · Cited by 8
Implementing Treatment Guidelines for Type 2 Diabetes in Primary Care
Brunton, S. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.03.1985 · Cited by 8
Valsamakis, G., Lois, K. B., Kumar, S., & Mastorakos, G. P. (2014) · Clinical Obesity · doi:10.1111/cob.12064 · Cited by 7
“arm, thus demonstrating pramlintide’s ability to achieve sustained body weight restriction (89).”
BackgroundEffects of pramlintide on energy intake and food preference in rats given a choice diet
Kern, K. A., DiBrog, A. M., Przybysz, J. T., & Mietlicki‐Baase, E. G. (2021) · Physiology & Behavior · doi:10.1016/j.physbeh.2021.113541 · Cited by 7
Patch, R. J., Zhang, R., Edavettal, S. C., Macielag, M. J., Eckardt, A. J., Li, J., Rives, M., Edwards, W., Hinke, S. A., Qiu, X., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114330 · Cited by 7
Bi, W., Zhou, W., Zhang, P., Sun, Y., Yue, W., & Lee, S. (2023) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2023.03.010 · Cited by 8
Synergistic long-range effects of mutations underlie aggregation propensities of amylin analogues
Alves, N. A., Dias, L. G., & Frigori, R. B. (2019) · Journal of Molecular Modeling · doi:10.1007/s00894-019-4137-x · Cited by 7
Pramlintide: A new tool in diabetes management
Want, L. L., & Ratner, R. E. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0004-0 · Cited by 7
Zukünftige Angriffspunkte für die Therapie des Typ-2-Diabetes
Stingl, H., & Roden, M. (2004) · Wiener klinische Wochenschrift · doi:10.1007/bf03041051 · Cited by 7
Ruddiman, K. R., Bartfield, J. K., & Hirsch, I. B. (2025) · Obesity · doi:10.1002/oby.70033 · Cited by 8
“Reported side effects and concerns with tachyphylaxis after about a year of treatment limit its popularity [145, 146].”
Pramlintide acetate in the treatment of Type 2 and Type 1 diabetes mellitus
Edelman, S. V., Schroeder, B. E., & Frías, J. P. (2006) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2.1.9 · Cited by 6
Kruger, D. F., Aronoff, S. L., & Edelman, S. V. (2007) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721707299766 · Cited by 6
“Combined Results from the 2 pramlintide pivotal trials in type 2 diabetes (data on file, Amylin Pharmaceuticals, Inc, San Diego, Calif).(17,22,23) *P < .”
Data-Driven Synthesis of Proteolysis-Resistant Peptide Hormones
Prothiwa, M., Syed, I., Huising, M. O., van der Meulen, T., Donaldson, C. J., Trauger, S. A., Kahn, B. B., & Saghatelian, A. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5065735 · Cited by 6
Obesity and Functional Gastrointestinal Disorders
Lee, K. J. (2012) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2012.59.1.1 · Cited by 6
“Amylin 유사체를 비만한 사람들에게 투여하면 체중이 줄고, leptin에 대한 반응이 회복된다.(12) 췌장 의 섬세포에서 분비되는 pancreatic polypeptide는 담낭을 이완시키고, 췌장액 분비를 억제하며 식욕을 감소시킨다.”
Elkind-Hirsch, K. E., Butler, W. J., Bhushan, M., Hirsch, D., & Bhushan, R. (2007) · Diabetes Care · doi:10.2337/dc07-0641 · Cited by 6
Kim, I., & Yun, J. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091098 · Cited by 9
Corrigan, R. R., Labrador, L., Grizzanti, J., Mey, M., Piontkivska, H., & Casadesús, G. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221057 · Cited by 5
Melander, S. A., Larsen, A. T., Karsdal, M. A., & Henriksen, K. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16329 · Cited by 5
“However, in trials where the insulin regimen was adjusted, no severe cases of hypoglycaemia were observed (Hollander et al., 2003; Holt et al., 2021; Whitehouse et al., 2002).”
BackgroundPharmacotherapy for obesity: a field in crisis?
Fenske, W. K., Parker, J., & Bloom, S. R. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.50 · Cited by 5
New Therapeutic Options for the Management of Diabetes
Sicat, B. L., & Morgan, L. (2007) · The Consultant Pharmacist · doi:10.4140/tcp.n.2007.45 · Cited by 5
Nuevas terapias en diabetes: más allá de la insulina inyectable y de los antidiabéticos orales
Feliciano-Alfonso, J. E., & Ariza, I. D. S. (2008) · Revista da Associação Médica Brasileira · doi:10.1590/s0104-42302008000500020 · Cited by 4
Management of New-Onset Diabetes Mellitus After Transplantation
Reynolds, L. R., & Tannock, L. R. (2008) · Postgraduate Medicine · doi:10.3810/pgm.2008.07.1792 · Cited by 4
Non-Insulin Treatments for Diabetes
Angueira-Serrano, E. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318235f2cb · Cited by 3
“These adverse events were reported in patients with type 2 diabetes with similar rates as those seen in patients with type 1 diabetes and were also transient in nature.(53,54)”
BackgroundGlycemic Control in Diabetic Patients on Long-Term Maintenance Dialysis
Aramwit, P., & Satirapoj, B. (2013) · InTech eBooks · doi:10.5772/52479 · Cited by 5
Analysis: Pramlintide: An Agent for Glycemic Control Plus Weight Control?
Riddle, M. C. (2002) · Diabetes Technology & Therapeutics · doi:10.1089/15209150252924102 · Cited by 4
Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives
Fu, L., Ding, R., Xu, G., Hu, J., & Yang, P. C. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156594 · Cited by 4
Mora, P., Aroda, V. R., Asong, M., Blüher, M., Carlander, A. F., Kaltoft, M., Vilsen, L. N., & Rosenstock, J. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01247-x · Cited by 3
Mora, P., Aroda, V. R., Asong, M., Blüher, M., Heftdal, L. D., Carlander, A. F., Vilsen, L. N., & Rosenstock, J. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01248-1 · Cited by 3
Brunzell, E., Sigfridsson, K., Gedda, L., Edwards, K., & Bergström, M. (2024) · Soft Matter · doi:10.1039/d3sm01172k · Cited by 3
Pramlintide: profile of an amylin analog
Lebovitz, H. E. (2012) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.12.50 · Cited by 3
Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults
Tarazi, M. S., Touhamy, S., Tchang, B. G., & Shukla, A. P. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1942841 · Cited by 3
“The main common adverse events from the study were nausea and headache [59].”
BackgroundCurrent trends in targeting the hormonal regulation of appetite and energy balance to treat obesity
Valentino, M. A., Colón‐González, F., Lin, J. E., & Waldman, S. A. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.33 · Cited by 3
Diabetes: The Latest Trends in Glycemic Control
Giurini, J. M., Cook, E. A., & Cook, J. J. (2007) · Clinics in Podiatric Medicine and Surgery · doi:10.1016/j.cpm.2006.12.001 · Cited by 3
Lush, C. W., Darsow, T., Zhang, B., Lorenzi, G. M., & Frías, J. P. (2007) · Insulin · doi:10.1016/s1557-0843(07)80060-1 · Cited by 3
Frigori, R. B., & Rodrigues, F. R. M. (2021) · Journal of Molecular Modeling · doi:10.1007/s00894-020-04617-9 · Cited by 3
“overcome by designing less amyloidogenic analogues of hIAPP [13], such as pramlintide (sIAPP) [14, 15], which is a chimeric-drug inspired in the naturally occuring (wildtype) aggregation-resistant rat isoform (rIAPP), whose triple proline substitutions (A25P, S28P, and S29P) act as β-sheet breakers [16, 17].”
BackgroundDiabetes drug update: how 4 new options stack up.
Taylor, & Campbell, K. M. (2007) · PubMed · Cited by 3
Kang, Z., Jin, Z., Wu, L., Sun, A., Dong, L., Li, J., Li, Q., & Tong, X. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s524000 · Cited by 3
A Review of Pramlintide in the Management of Diabetes
Messer, C., & Green, D. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2369 · Cited by 2
Palumbo, P. J., & Wert, J. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s8564 · Cited by 2
What Have We Learned About the Treatment of Type 2 Diabetes? The Evolving Paradigms
Freeman, J. S., & Horton, E. S. (2012) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31826fc5e5 · Cited by 2
“Another study showed that pramlintide sustained reduction of A1C from baseline values and was accompanied with weight loss, compared with insulin (with or without oral antidiabetics).(75) In addition to amylin analogs, 2 new approaches for therapy, which involve targeting the incretin system and the kidneys, have been…”
ResultTreatment Considerations for Diabetes: A Pharmacist’s Guide to Improving Care in the Elderly
Nicholas, A., Nadeau, D. A., & Johnson, A. C. L. (2009) · Journal of Pharmacy Practice · doi:10.1177/0897190009333160 · Cited by 2
“Hypoglycemia tended to occur in the first month of pramlinitide therapy when preprandial insulin doses, in conjunction with approved doses of pramlinitide, were not adjusted downward.(111) Also, because it too is administered subcutaneously, there may be adherence problems because of 3 additional injections daily in c…”
BackgroundChoe, C. H., & Edelman, S. V. (2007) · Southern Medical Journal · doi:10.1097/01.smj.0000286751.78656.45 · Cited by 2
“62 at 52 weeks.(55) Pramlintide significantly reduced postprandial glucose excursions by 81% when administered just before meals in type 2 diabetes patients using insulin lispro (P 0.”
BackgroundIs Weight Gain an Unavoidable Consequence of Insulin Therapy?
(2007) · The Internet Journal of Internal Medicine · doi:10.5580/1cb5 · Cited by 2
Brusegan, A., McKay, G., & Llano, A. (2020) · Practical Diabetes · doi:10.1002/pdi.2300 · Cited by 2
Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes
Corsino, L., Cox, M. E., Rowell, J. V., & Green, J. B. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2109 · Cited by 2
New treatments of diabetes: The β-amylin agonists
Lebovitz, H. E. (2008) · Annales d Endocrinologie · doi:10.1016/j.ando.2008.02.015 · Cited by 2
Martin, C. L. (2007) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721706298434 · Cited by 2
Considering Pramlintide Therapy for Postprandial Blood Glucose Control
Childs, B. P., Kesty, N. C., KLEIN, E. J., Rubin, R. R., & Wick, A. (2007) · Diabetes Spectrum · doi:10.2337/diaspect.20.2.108 · Cited by 2
The Role of Calcitonin Gene-Related Peptide and Amylin in Pediatric Migraine
Aydın, H., & Baykan, Ö. (2024) · Neuropediatrics · doi:10.1055/s-0044-1788787 · Cited by 1
“19,20 Although the mechanisms involved in these adverse effects of pramlintide are not fully understood, nausea is thought to be mediated by the stimulation of speci fi c amylin receptors in the circum-ventricular area postrema through activation of the solitary nucleus.”
The Art and Science of Antidiabetic Medications and Obesity Management
Sawhney, S. K., Kapri, A., Chaudhary, G., & Chauhan, B. (2025) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575413887251001111806 · Cited by 1
Peptide drugs for obesity and type 2 diabetes mellitus: an overview of clinical trials
Barzgar, H., Darmadi, D., Nafisa, J., Narkulov, S., & Sviridova, M. B. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120772 · Cited by 2
Alhazmi, A., & le Roux, C. W. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71074 · Cited by 1
Pharmacologic Approaches to Type 2 Diabetes and Obesity in Children and Adolescents
Pongsuwan, P. (2011) · Humana Press eBooks · doi:10.1007/978-1-60327-256-8_12 · Cited by 1
Type 2 Diabetes and Concomitant Illness
Dungan, K. M., Harris, E., & Braithwaite, S. S. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-043-4_14 · Cited by 1
Diagnosis, Evaluation, and Medical Management of Obesity and Diabetes
Chan, J. L., & Mantzoros, C. S. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-453-1_16 · Cited by 1
New concepts in diabetes: how multihormonal regulation can improve glycemic control.
Blonde, L., Baker, D. E., Davis, S. N., & Ratner, R. E. (2004) · PubMed · Cited by 1
(2007) · The Internet Journal of Advanced Nursing Practice · doi:10.5580/1ba5 · Cited by 1
“diabetes in studies of up to one year (55, 56, 57).”
BackgroundObesity: Medical and Surgical Treatment
Tassinari, D., Giovanelli, A., & Asteria, C. (2021) · Springer eBooks · doi:10.1007/978-3-030-80267-7_9 · Cited by 1
Frigori, R. B. (2024) · The European Physical Journal B · doi:10.1140/epjb/s10051-024-00796-z · Cited by 1
Does addition of pramlintide to basal insulin improve glycemic control in type 2 diabetes mellitus?
Edelman, S. V. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0760 · Cited by 1
“The amylin analog pramlintide has been extensively studied in both type 1 and insulin-requiring type 2 diabetes mellitus with very consistent clinical effects, namely significant and sustained glucose control (mainly due to reductions in postprandial glucose levels), reduced glucose fluctuations, and sustained weight…”
BackgroundInsulin, glucagon, and hypoglycemic drugs
Krans, H. M. J. (2003) · Side effects of drugs annual · doi:10.1016/s0378-6080(03)80049-1 · Cited by 1
Combination Therapy for Treatment of Type 2 Diabetes
McCall, A. L. (2007) · CRC Press eBooks · doi:10.3109/9780849379581-16 · Cited by 1
Hensen, J. (2007) · CRC Press eBooks · doi:10.3109/9780849379581-18 · Cited by 1
Advances in the management of type 2 diabetes mellitus
Moustafa, N. (2012) · The Egyptian Journal of Internal Medicine · doi:10.7123/01.ejim.0000418015.54092.98 · Cited by 1
Adjunctive Therapy, Including Pharmacotherapy
Al-Bazz, D. Y., & Wilding, J. P. H. (2022) · Wiley eBooks · doi:10.1002/9781119695257.ch21 · Cited by 1
What is the role of amylin as an emerging therapeutic agent in obesity?
Bogaerts, G., Lommi, G., & Lutz, T. A. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2668391 · Cited by 1
“Longer-term randomized trials showed that adjunct pram-lintide therapy improves HbA1c and leads to modest reductions in body weight, despite lower mealtime insulin requirements [8].”
InfluentialGastrointestinal Hormones and Obesity
Wang, Y., & Kokkotou, E. G. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1607-5_6
“Thus non-amyloidogenic amylin analogs (pramlintide) have been developed and approved for the treatment of diabetes [90, 93 ].”
BackgroundPharmacotherapy Of Type 2 Diabetes – The Future
Abhay, A. P., Ravichand, D. M., V.Seshayamma, & Chandran, P. (2006) · Intern J Endocrinol Metab
Zukunftsperspektiven der medikamentösen Therapie bei Adipositas
Pichler, B., & Ludvik, B. H. (2003) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Codario, R. A. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-441-8_8
Monte, S. V., Schentag, J. J., Adelman, M. H., & Paladino, J. A. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400220
Evaluating and Treating Cardiometabolic Risk Factors: A Case Discussion
Haines, S. T., Fuke, D. C., Lender, D., Rodgers, P. T., & Clough, S. S. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.5part2.32s
Pramlintide in the Management of Obesity
Jones, M. C., DeBellis, H. F., & Barefield, K. L. (2010) · Clinical Medicine Reviews in Therapeutics · doi:10.4137/cmrt.s4021
Utilization Of Oral Anti-diabetic Medications: Examining Adherence To Clinical Guidelines
Rao, S. (2011) · Figshare
OBESE DIABETIC PATIENTS: IMPACT OF DIFFERENT MANAGEMENT MODALITIES
Dampanaboina, K., Bitra, V. R., & Annapurna, A. (2012) · Iranian journal of diabetes and obesity
Freemark, M. (2005) · CRC Press eBooks · doi:10.1201/9781420038798.ch11
Non‐Insulin Parenteral Therapies
Vilsbøll, T., Christensen, M., Jorsal, T., & Knop, F. K. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch32
The Challenges and Opportunities of Managing Diabetes in Long-Term Care
Marasco, R. A., Samos, L. F., & Pandya, N. (2008) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2008.04.005
Features of treatment of type 2 diabetes mellitus in patients with concomitant pathology
Shlyakhto, E. V., Grineva, E. N., Babenko, A. Y., & Владимировна, Д. А. (2009) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2009-15-1-31-41
Choosing Medications for Weight Loss in Type 2 Diabetes Mellitus
Jagasia, S. M., Hendrickson, C. D., & Williams, A. J. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch15
Non-insulin agents in the management of type 2 diabetes
Fonseca, V. A., Pendergrass, M., & McDuffie, R. H. (2009) · Springer eBooks · doi:10.1007/978-1-84882-103-3_3
Pramlintide Acetate in the Treatment of Type 2 Diabetes
Edelman, S. V., Schroeder, B. E., & Frías, J. P. (2007) · CRC Press eBooks · doi:10.3109/9780849379581-14 · Cited by 2
Insulin, glucagon, and hypoglycemic drugs
Krans, H. M. J. (2004) · Side effects of drugs annual · doi:10.1016/s0378-6080(04)80049-7
(2006) · Elsevier eBooks · doi:10.1016/b0-44-451005-2/00981-5
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00291-2
Cada, D. J., Levien, T. L., & Baker, D. E. (2005) · Hospital Pharmacy · doi:10.1177/001857870504000709
INSULINS AND OTHER HYPOGLYCEMIC DRUGS
(2009) · Elsevier eBooks · doi:10.1016/b978-0-444-53271-8.50008-9
Current literature in diabetes
John Wiley & Sons, L. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.466
Pagenkemper, J. J. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-032-4_6
Metadata
- Authors
- Hollander, P. A., Levy, P., Fineman, M. S., Maggs, D. G., Shen, L. Z., Strobel, S. A., Weyer, C., & Kolterman, O. G.
- Affiliations
- Baylor University Medical Center (US)
- Phoenix Endocrinology Clinic, Phoenix, Arizona
- Amylin Pharmaceuticals, Inc., San Diego, California
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2003-03-01
- Volume
- 26
- Issue
- 3
- Pages
- 784-790
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2045554373
- Cited by
- 307
- References
- 32
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 10 · 2023: 6 · 2022: 8 · 2021: 12 · 2020: 9 · 2019: 4 · 2018: 5 · 2017: 8 · 2016: 13 · 2015: 8 · 2014: 10 · 2013: 11 · 2012: 14
- FWCI
- 10.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- pramlintide, amylin analogues, type 2 diabetes, insulin therapy, glycemic control, HbA1c, weight loss, hypoglycemia, nausea, long-term efficacy and safety
- MeSH terms
- Aged, Amyloid, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Male, Middle Aged, Incidence, Treatment Outcome, Islet Amyloid Polypeptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
